United States

Profile: T2 Biosystems Inc (TTOO.A)

TTOO.A on American Stock Exchange

16 Aug 2019
Change (% chg)

$0.04 (+4.61%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

T2 Biosystems, Inc., incorporated on April 27, 2006, is an in vitro diagnostics company that is engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company is focused on developing and launching commercially its diagnostic products aimed at reducing mortality rates, improving patient outcomes and reducing the cost of healthcare. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements.

The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel, which have the ability to rapidly identify the clinically relevant species of Candida, a fungal pathogen known to cause sepsis. T2Dx is a bench-top instrument that can run a range of diagnostic tests, and is automated from patient sample input to result. The initial panels designed to run on T2Dx are T2Candida and T2Bacteria, which are focused on identifying pathogens associated with sepsis. The Company is also applying T2MR to develop T2Plex. T2Plex will run the Company's T2HemoStat panel, which includes a set of hemostasis measurements, including platelet function, clotting time and clot degradation, also known as fibrinolysis.

T2MR enables sepsis applications, including T2Candida and T2Bacteria that can identify specific sepsis pathogens directly from an unpurified blood sample. It is also developing T2Bacteria, a multiplex diagnostic panel that detects the bacterial pathogens associated with sepsis that are not covered by first-line antibiotics. The Company completed a pivotal clinical trial for its T2Dx Instrument and its T2Candida Panel. The Company's T2Stat and T2HemoStat utilize T2MR, and are designed to provide hemostasis measurements in approximately 45 minutes. T2HemoStat is a panel of diagnostic tests that provides data across the hemostasis spectrum, including measurements of clotting time, platelet activity, clot contraction and clot lysis.

The Company competes with Becton Dickinson & Co., bioMerieux, Inc., Bruker Corporation, Nanosphere, Inc., Cepheid, Danaher, Abbott, Accelerate Diagnostics, Inc., BioFire Diagnostics, Inc. and Siemens AG.

Company Address

T2 Biosystems Inc

101 Hartwell Ave
LEXINGTON   MA   02421-3125
P: +1781.4571200
F: +1781.3573080

Company Web Links